Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer
| Autor: | Roy Morten Kristensen, Frid Sofie Lichtwarck Bjugn, Elin Storjord, Ole-Lars Brekke |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Bicalutamide Antineoplastic Agents Hormonal Urology 030232 urology & nephrology Calcium oxalate Allopurinol Antineoplastic Agents Urine 030204 cardiovascular system & hematology Adenocarcinoma Tosyl Compounds 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Nitriles medicine Humans Anilides Acute intermittent porphyria Aged business.industry Goserelin Prostatic Neoplasms Androgen Antagonists Hyperuricosuria medicine.disease Treatment Outcome chemistry Nephrology Porphyria Acute Intermittent Uric acid business medicine.drug |
| Zdroj: | Scandinavian journal of urology. 53(2-3) |
| ISSN: | 2168-1813 |
| Popis: | Studies of patients with hyperuricosuria have provided four kinds of evidence linking their hyperuricosuria to calcium stone formation and identifying them as a distinct entity apart from other calcium stone formers. The evidence includes a more virulent natural history of stone disease, in vitro evidence for heterogeneous nucleation of calcium oxalate crystallization by seed crystals for uric acid or sodium hydrogen urate, and a reduction by uric acid or urate of the inhibitory activity which urine normally has upon calcium oxalate crystal growth. The fourth bit of evidence, the dramatic reduction in stone formation rates with allopurinol treatment, will be discussed in detail in a following paper. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |